Intratumorally anchored cytokine therapy.

ABSTRACT:

Introduction

On-target, off-tumor toxicity severely limits systemic dosing of cytokines and agonist antibodies for cancer. Intratumoral administration is increasingly being explored to mitigate this problem. Full exploitation of this mode of administration must include a mechanism for sustained retention of the drug; otherwise, rapid diffusion out of the tumor eliminates any advantage.

Areas covered

We focus here on strategies for anchoring immune agonists in accessible formats. Such anchoring may utilize extracellular matrix components, cell surface receptor targets, or exogenously administered particulate materials. Promising alternative strategies not reviewed here include slow release from the interior of a material depot, expression following local transfection, and con

SUBMITTER: Wittrup KD 

PROVIDER: S-EPMC9262866 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature